Nanobiotix (NASDAQ: NBTX) announced the FDA accepted a protocol amendment to its ongoing Phase 3 head and neck cancer study ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE